Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 5/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.47 |
| ▸ | CDK9 | P50750 | 4/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633769 | 0.92 | HRH3 (0.43) | RIPK2CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL1634293 | 0.91 | MAP4K1 (0.48) | CDK2CCNA2CDK5CDK5R1CCNT1 | |
| SCHEMBL12724944 | 0.90 | MARK3 (0.46) | RIPK2CDK2CCNA2CCNT1CDK9 | |
| SCHEMBL1633265 | 0.87 | SYK (0.54) | RIPK2CDK2CCNA2CDK5CDK5R1 | |
| SCHEMBL1634247 | 0.84 | SCN9A (0.46) | HRH3 | |
| SCHEMBL12724921 | 0.84 | SYK (0.44) | HRH3SYKPKMYT1 | |
| SCHEMBL1632964 | 0.84 | USP2 (0.49) | CDK2CCNA2CDK5CDK5R1MAPK1 | |
| SCHEMBL1632439 | 0.84 | TTK (0.50) | RIPK2CDK2CCNA2CCNT1CDK9 | |
| SCHEMBL1633193 | 0.82 | EGFR (0.46) | — | |
| SCHEMBL1634285 | 0.82 | MAP4K1 (0.55) | CDK2CCNA2CDK5CDK5R1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | RIPK2 578/4885CDK2 29/4885CCNA2 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.